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On November 14-15, 2008, the third Scandinavian COPD
Research Symposium was held at Holmenkollen Park
Hotel Rica, Oslo, Norway. Like the previous meetings,
arranged 2004 (1) and in 2006 (2), the purpose was to
let young scientists from our countries come together
and present their current COPD-related research. The
meeting should also facilitate collaboration and
stimulate further research in the field of COPD. For the
first time, Finland joined the symposium and eleven
young scientists from Denmark Finland, Norway and
Sweden presented their latest data and five State-of-
the-Art lecturers covered two sessions. “Inflammation
and structural changes in COPD’’ and “COPD – co-
morbidities’’. The meeting was generously supported by
grants from Boehringer-Ingelheim and Pfizer.
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The role of inflammation in the pathogenesis of COPD
has been emphasised during the last years, and this area
is now intensively researched. The current concept of
inflammation as a response to environmental noxious
agents, as cigarette smoke resulting in a local airway
inflammation is getting increasing evidence. However,
recently systemic inflammation has been studied, where
still the hen and egg debate between local and systemic
effects is ongoing.
The local inflammation in the airway is involving
innate and adaptive immune reactions. Throughout the
airway inflammatory reactions are seen, most well
studied in morphological samples of smokers with and
without COPD. In most patients there is a central
bronchitis seen, with inflammatory cells, hypertrophia
of mucous producing cells and glands. In the bronchioles
the inflammation can be intensive in spite of relatively
mild COPD. Emphysema can occur early in the develop-
ment of disease, and recently it has also been empha-
sised that there is often an intensive vascular inflam-
mation in COPD lungs. Most inflammatory cells are
recruited and activated in the airways of COPD patients.
The epithelium as the first resort for noxious agents is
activated, with certain pro-inflammatory activities.
Macrophages are recruited to both the airway paren-
chyma and perhaps more important to the airway
lumen, the obvious reason being phagocytosis particles
in the cigarette smoke. They also take part in the
further recruitment of inflammatory cells as neutro-
phils. Both macrophages and neutrophils produce pro-
teases, with important effects on the alveolar structure
during emphysema development. Both cell types also
produce oxygen radicals, which further enhances the
inflammatory reaction, and also decreases the ant-
protease activity in the airway. Lymphocyte reactions
seem to be abundant in the COPD inflammation, and the
number of cytotoxic T-lymphocytes(CD8 positive) is well
correlated to the severity of the disease, with early
changes also in the preclinical phase. A more recent
finding is that the adaptive immune system is involved
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in the formation of lymphocyte follicles in the lungs,
more common in advanced disease, and dominated by
B-lymphocytes. Cells more commonly described in
asthma pathogenesis also seem to be involved in COPD.
Eosinophils are more common in central airways
biopsies in smokers than in non-smokers, and these cells
are more commonly seen in the mucosa during COPD
exacerbations. Mast cells have also been seen in central
airways in smokers, and recently their occurrence in
peripheral airways is under investigation.
The issue of systemic inflammation is also under
intensive research currently, with certain emphasis on
comorbid conditions in COPD. Of special interest is the
coupling between COPD and cardiovascular disorders,
mostly related to atherosclerosis. Very recent results
from our group indicate that vulnerability for systemic
inflammatory reactions could be a risk factor for the
development of COPD, as elevation of acute phase
proteins in subjects clearly increased the risk of being
hospitalised decades after the measurement of the
acute phase proteins (Engstrom G et al. Thorax 2009, e-
publication).
The concept of inflammation in COPD is under
development, and hopefully this knowledge will in the
future increase the treatment possibilities in COPD.
Structural changes in COPD: Remodelling in COPD
and asthma: differences and similarities
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Remodelling can be defined as alteration of tissue archi-
tecture. This dynamic process involves a number of cells
including structural cells and occurs both during normal
organ development and in response to injury. Chronic
inflammation and remodelling are linked, and may
result difficulties in maintaining normal tissue function.
Diagnosis of asthma and COPD is based upon limitation
of expiratory airflow. The pathophysiological correlates
to this lung function impairment are complex but are
associated with development of structural changes in the
airways and lung parenchyma. In addition, the preceding
inflammation differs, both between the two diseases,
but also between various airway and lung compartments
and may also differ from one patient to another. Both
asthma and COPD are heterogeneous disorders including
various phenotypes and there is a considerable overlap
between two the diseases.
In asthma, airways obstruction is thought to be
predominately located in the large airways. Thus,
epithelial desquamation, subepithelial fibrosis and
increased smooth muscle mass are seen and may,
together with inflammatory infiltration lead to airway
narrowing. Recent studies have, however, indicated that
inflammation and probably also remodelling in asthma
are also present in other compartments in the lung, such
as the small airways.
In the large airways in COPD, there is an increased
amount of goblet cells and glands which may result in
the clinical picture of chronic bronchitis. However, the
large airways are not the major site of the airways
obstruction in COPD. Instead, structural changes in the
small airways and lung parenchyma are the main
correlates for the limitation of expiratory airflow. In the
small airways, peribronchiolar fibrosis (bronchiolitis),
are seen and the wall thickness in COPD have been
found to correlate to forced expiratory volume in one
second (FEV1). Bronchiolitis in COPD may be accom-
panied by emphysema, i.e. destruction of alveolar walls
resulting in a decreased gas exchange area.
Thus, localization of the structural changes differs
between the two diseases suggesting that they should
be treated differently. Currently, the main pharmaco-
logical treatment of asthma and COPD are broncho-
dilators and glucocorticoids. It seems that the more
distal in the lung the remodeling occur, the more
irreversible it is to this available treatment.
In COPD and severe asthma, available pharmaco-
therapy has not proven to restore lung function
impairment. It is therefore increasingly recognized that
research aiming to explore mechanisms of airway
remodeling should be encouraged. This may lead to
development of new therapeutic strategies in order to
interfere with the biology of structural cells, hopefully
resulting in a possible restoration of lung architecture.
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Chronic obstructive pulmonary disease (COPD) is
defined by chronic airflow limitation associated with an
abnormal pulmonary inflammatory response of the lungs
to inhaled particles and gases, usually cigarette smoke.
However, it is now recognised that in addition to the
effects in the lungs COPD, like many chronic diseases
has systemic consequences which result in comorbities
which influence both morbidity and mortality.
The cause of these systemic effects is not well
understood but is thought to result from a systemic
inflammatory response, which produces the systemic
effects such as weight loss, muscle wasting, and
increased risk of cardiovascular disease, metabolic
syndrome, cancer and osteoporosis. The ageing process
is characterised by progressive, generalised impairment
of function resulting in an increasing vulnerability to
environmental challenge and an increased risk of
disease. Accelerated ageing is a further hypothesis
which could account for both the local lung and
systemic effects of COPD.
The diagnosis and assessment of severity of COPD
may be greatly affected by the presence of co morbid
conditions and it may be that in addition to lung
function measurements, assessment of cardiovascular
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